These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33782404)

  • 1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    Martin M; Ramos-Medina R; Bernat R; García-Saenz JA; Del Monte-Millan M; Alvarez E; Cebollero M; Moreno F; Gonzalez-Haba E; Bueno O; Romero P; Massarrah T; Echavarria I; Jerez Y; Herrero B; Gonzalez Del Val R; Lobato N; Rincon P; Palomero MI; Marquez-Rodas I; Lizarraga S; Asensio F; Lopez-Tarruella S
    Sci Rep; 2021 Mar; 11(1):7064. PubMed ID: 33782404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome 12p Amplification in Triple-Negative/
    Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Sole A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monso MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E
    Cancer Res; 2019 Aug; 79(16):4258-4270. PubMed ID: 31213465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
    [No Abstract]   [Full Text] [Related]  

  • 4. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
    Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
    Du F; Wang W; Wang Y; Li M; Zhu A; Wang J; Cai R; Ma F; Fan Y; Li Q; Zhang P; Todorovic V; Yuan P; Xu B
    Breast Cancer Res Treat; 2020 Jul; 182(1):67-77. PubMed ID: 32394350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
    Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
    Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
    Sikov WM; Berry DA; Perou CM; Singh B; Cirrincione CT; Tolaney SM; Kuzma CS; Pluard TJ; Somlo G; Port ER; Golshan M; Bellon JR; Collyar D; Hahn OM; Carey LA; Hudis CA; Winer EP
    J Clin Oncol; 2015 Jan; 33(1):13-21. PubMed ID: 25092775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of synergistic drug combinations using breast cancer patient-derived xenografts.
    Turner TH; Alzubi MA; Harrell JC
    Sci Rep; 2020 Jan; 10(1):1493. PubMed ID: 32001757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
    Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
    Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
    Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
    Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
    Park HS; Lee JD; Kim JY; Park S; Kim JH; Han HJ; Choi YA; Choi AR; Sohn JH; Kim SI
    PLoS One; 2019; 14(12):e0225082. PubMed ID: 31821346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
    Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
    Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
    Kern P; Kalisch A; Kolberg HC; Kimmig R; Otterbach F; von Minckwitz G; Sikov WM; Pott D; Kurbacher C
    Chemotherapy; 2013; 59(5):387-94. PubMed ID: 24852315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
    Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
    Ademuyiwa FO; Chen I; Luo J; Rimawi MF; Hagemann IS; Fisk B; Jeffers G; Skidmore ZL; Basu A; Richters M; Ma CX; Weilbaecher K; Davis J; Suresh R; Peterson LL; Bose R; Bagegni N; Rigden CE; Frith A; Rearden TP; Hernandez-Aya LF; Roshal A; Clifton K; Opyrchal M; Akintola-Ogunremi O; Lee BH; Ferrando-Martinez S; Church SE; Anurag M; Ellis MJ; Gao F; Gillanders W; Griffith OL; Griffith M
    Breast Cancer Res Treat; 2021 Aug; 189(1):187-202. PubMed ID: 34173924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
    Kern P; Kalisch A; von Minckwitz G; Pütter C; Kolberg HC; Pott D; Kurbacher C; Rezai M; Kimmig R
    J Chemother; 2016 Jun; 28(3):210-7. PubMed ID: 26239282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
    Yamada M; Kubo M; Kai M; Yamamoto H; Nakamura M
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):703-705. PubMed ID: 28860445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.